Middle Meningeal Artery Embolization in the Treatment of Chronic Subdural Hematoma: A Two-Center Retrospective Study
Authors:
- Francesco AdduciFAFrancesco Adduci
- Bruno Del SetteBSBruno Del Sette
- Giancarlo SalsanoGSGiancarlo Salsano
- Greta VenturiGVGreta Venturi
- Carmelo SturialeCSCarmelo Sturiale
- Massimo Dall’olioMDMassimo Dall’olio
- Claudia Rolla BiglianiCBClaudia Rolla Bigliani
- Pietro FiaschiPFPietro Fiaschi
- Luigi CirilloLCLuigi Cirillo
- Lucio CastellanLCLucio Castellan
Open Access
- 20 November 2025
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (22) , 8226
Abstract
Background: Chronic subdural hematoma (cSDH) is a common condition, particularly in individuals over 65 years of age. Its pathophysiology involves traumatic and inflammatory processes, culminating in hematoma formation. Although surgical drainage is the primary treatment of choice, its significant recurrence rates have prompted exploration of non-surgical options. This study evaluates the effectiveness of middle meningeal artery (MMA) embolization as an alternative or adjunctive treatment in asymptomatic or paucisymptomatic cSDH patients. Methods: This two-center retrospective study analyzed 93 patients treated with MMA embolization at two hospitals between 2020 and 2024. Patients exhibited either asymptomatic or mild symptomatic cSDH (Markwalder score 0 or 1), with hematoma thickness >10 mm. Pre- and post-treatment CT scans were compared to assess hematoma thickness, with follow-ups conducted at three months. Statistical analysis included ANCOVA and Mann–Whitney U tests for outcome evaluation. Results: Of the 93 patients, 44 underwent bilateral embolization, and 49 underwent unilateral embolization. Treatment reduced hematoma thickness by an average of 59% at three months follow-up. The trabecular subtype showed the greatest thickness reduction compared to other subtypes (p < 0.05). No significant differences were found between embolization materials. Only 3.2% of patients experienced technical complications, and three patients experienced rebleeding during follow-up. Conclusions: MMA embolization appears to be a safe and effective treatment for cSDH, providing a minimally invasive alternative to surgery. The technique shows promise in reducing hematoma size, especially in the trabecular subtype. Further research is needed to confirm these findings and establish their role in routine clinical practice.Keywords
This publication has 27 references indexed in Scilit:
- Meningeal Embolization for Preventing Chronic Subdural Hematoma Recurrence After SurgeryJAMA, 2025
- Embolization of the Middle Meningeal Artery for Chronic Subdural HematomaNew England Journal of Medicine, 2025
- Adjunct Middle Meningeal Artery Embolization Versus Surgery for Chronic Subdural Hematoma: A Systematic Review and Meta-AnalysisNeurosurgical Review, 2024
- Middle Meningeal Artery Embolization for Nonacute Subdural HematomaNew England Journal of Medicine, 2024
- Failure Rates of Conservative Management of Minimally Symptomatic Chronic Subdural Hematoma: A Systematic Review and Meta-AnalysisWorld Neurosurgery, 2024
- Middle Meningeal Artery Embolization for Membranous Versus Nonmembranous Subdural Hematomas: A Retrospective and Multicenter Cohort StudyWorld Neurosurgery, 2023
- Middle Meningeal Artery Embolization Versus Conventional Treatment of Chronic Subdural HematomasNeurosurgery, 2021
- Middle Meningeal Artery Embolization for Chronic Subdural Hematoma: A Multi-Center Experience of 154 Consecutive EmbolizationsNeurosurgery, 2020
- Middle Meningeal Artery Embolization for Chronic Subdural Hematoma: Meta-Analysis and Systematic ReviewWorld Neurosurgery, 2019
- Which surgical procedure is effective for refractory chronic subdural hematoma? Analysis of our surgical procedures and literature reviewJournal of Clinical Neuroscience, 2018